drugset / Trial / NCT07308574
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Timeline
- Start
- 2025-12-19
- Primary completion
- 2027-06-25
- Completion
- 2027-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ravulizumab | Monoclonal antibody | — | Intravenous |